-
1 month ago | 
targetedonc.com | Rohit Gosain |Rahul Gosain |Toni K. Choueiri
2 Commerce Drive Cranbury, NJ 08512
-
2 months ago | 
onclive.com | Toni K. Choueiri
CommentaryVideoJanuary 29, 2025Author(s):Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma. “HIF-2α governs the activity of multiple genes downstream involved in RCC carcinogenesis and the proliferation of VEGF and other [disease factors]. There has been a lot of work on targeting [HIF-2α via] another mechanism that could be central, more active, and more beneficial [than available therapies].”Toni K.
-
Sep 26, 2024 | 
onclive.com | Toni K. Choueiri
CommentaryVideoSeptember 26, 2024Author(s):Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma. Toni K.
-
Sep 15, 2024 | 
onclive.com | Toni K. Choueiri
CommentaryVideoSeptember 15, 2024Author(s):Fact checked by:Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.
-
Sep 13, 2024 | 
urotoday.com | Toni K. Choueiri
Read the Full Video TranscriptPedro Barata: Hi, everyone. I'm Pedro Barata, a GU oncologist at University Hospitals Seidman Cancer Center here in Cleveland. It is a true privilege to be here sitting down with Dr. Toni Choueiri. Everybody knows Toni, everybody knows you. Toni is the director of the Lank Center for GU Oncology at the Dana-Farber Cancer Institute, a world-renowned kidney cancer and GU expert.
-
Sep 13, 2024 | 
urotoday.com | Toni K. Choueiri
Read the Full Video TranscriptPedro Barata: Hi, everyone. I'm Pedro Barata, a GU oncologist at University Hospitals Seidman Cancer Center here in Cleveland. It is a true privilege to be here sitting down with Dr. Toni Choueiri. Everybody knows Toni, everybody knows you. Toni is the director of the Lank Center for GU Oncology at the Dana-Farber Cancer Institute, a world-renowned kidney cancer and GU expert.
-
Aug 28, 2024 | 
nature.com | Toni K. Choueiri
Correction to: Nature Medicine https://doi.org/10.1038/s41591-020-1093-z, published online 5 October 2020. In the version of the article initially published, in Fig. 1, the label now reading “HIF1β” originally read “HIF2α” and has now been corrected in the HTML and PDF versions of the article. About this articleChoueiri, T.K., Kaelin, W.G. Author Correction: Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat Med (2024).
-
Aug 21, 2024 | 
healio.com | Josh Friedman |Mindy Valcarcel |Toni K. Choueiri
You've successfully added Genitourinary Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Belzutifan improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma.
-
Jul 11, 2024 | 
onclive.com | Toni K. Choueiri
CommentaryVideoJuly 11, 2024Author(s):Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma. Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, Kidney Cancer Program, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the phase 3 TiNivo-2 study (NCT04987203) in pretreated advanced renal cell carcinoma (RCC).
-
Jun 20, 2024 | 
targetedonc.com | Rahul Gosain |Rohit Gosain |Toni K. Choueiri
2 Commerce Drive Cranbury, NJ 08512
